Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib

Anaplastic Lymphoma Kinase (ALK)

on chromosome 2p23, and codes for a protein that is expressed in some cells of the central nervous system, but in virtually no other normal human cells. Interest in this protein among diagnostic pathologists has been related to its utility in recognizing a subset of CD30+ anaplastic large cell lymphomas (ALCL's), that show a characteristic t(2;5)(p23;q35) translocation. This translocation resul...

ALK (anaplastic lymphoma kinase)

Description 1620 amino acids; 177 kDa; after glycosylation, produces a 200 kDa mature glycoprotein; composed of an extracellular domain, a transmembrane domain, a tyrosine kinase domain, and an intracytoplasmic domain in C-term; dimerization. Expression Is tissue specific; mainly in: brain, gut and testis; not in the lymphocytes. Localisation Cell membrane. Function Membrane associated tyrosine...

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance

The development of inhibitors for the tyrosine anaplastic lymphoma kinase (ALK) has advanced rapidly, driven by biology and medicinal chemistry. The first generation ALK inhibitor crizotinib was granted US FDA approval with only four years of preclinical and clinical testing. Although this drug offers significant clinical benefit to the ALK-positive patients, resistance has been developed throu...

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor

This is the first report in which crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, reduced an atypical carcinoid tumor with ALK rearrangement. A 70-year-old man developed a tumor in the left lung and multiple metastases to the lung and brain. The pathology of transbronchial biopsied specimens demonstrated an atypical carcinoid pattern. Combined with immunohistochemical findings, we di...

ALK- negative Anaplastic Large Cell Lymphoma of Bone